Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Paola Claudia Sacco"'
Autor:
Paolo Maione, Paola Claudia Sacco, Assunta Sgambato, Francesca Casaluce, Antonio Rossi, Cesare Gridelli
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 7 (2015)
The discovery that a number of aberrant tumorigenic processes and signal transduction pathways are mediated by druggable protein kinases has led to a revolutionary change in nonsmall cell lung cancer (NSCLC) treatment. Epidermal growth factor recepto
Externí odkaz:
https://doaj.org/article/94fdebc8d06643ebb0af4c35d0a155b0
Autor:
Paolo Maione, Antonio Rossi, Paola Claudia Sacco, Maria Anna Bareschino, Clorinda Schettino, Marianna Luciana Ferrara, Marzia Falanga, Rita Ambrosio, Cesare Gridelli
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 2 (2010)
More than 40% of cases of all lung cancers are diagnosed in patients over the age of 70 years. Elderly patients have more comorbidities and tend to be less tolerant to toxic medical treatments than their younger counterparts. Thus, clinical data obta
Externí odkaz:
https://doaj.org/article/c9df527611e745cdbdacab043b2ac4dc
Autor:
Clorinda Schettino, Maria Anna Bareschino, Antonio Rossi, Paolo Maione, Vincenzo Castaldo, Nicole Mazzeo, Paola Claudia Sacco, Marianna Luciana Ferrara, Giovanni Palazzolo, Fortunato Ciardiello, Cesare Gridelli
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 1 (2009)
Improving outcomes for early-stage non-small cell lung cancer (NSCLC) is a major research area considering that a significant percentage of such patients develop recurrent disease within 5 years of complete lung resection. Adjuvant chemotherapy prolo
Externí odkaz:
https://doaj.org/article/0a672a3bbcb74d109d19f2c65474c5ff
Publikováno v:
Expert Review of Respiratory Medicine. 12:783-792
INTRODUCTION Lung cancer is predominantly a disease that affects the elderly; about 30-40% of lung cancers are diagnosed in patients aged 70 or more. The increasing number of elderly patients over the next decades is generating a new social and healt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e18736df79770ea12f83076aa48e1de9
https://doi.org/10.1080/17476348.2018.1510322
https://doi.org/10.1080/17476348.2018.1510322
Autor:
Assunta Sgambato, Cesare Gridelli, Francesca Casaluce, Paola Claudia Sacco, Paolo Maione, Giuseppe Santabarbara
Publikováno v:
Expert Opinion on Investigational Drugs. 26:973-984
KRAS is the most frequently mutated oncogene in NSCLC, occurring in around a third of patients. However, this largest genomically defined subgroup of lung cancer patients seem to remain 'undruggable', with any effective targeted therapy approved at t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcc692bdfcd9b26e76087cb7969ba9fc
https://doi.org/10.1080/13543784.2017.1351543
https://doi.org/10.1080/13543784.2017.1351543
Autor:
Antonio Rossi, M L Barzelloni, Francesca Casaluce, Paola Claudia Sacco, Cesare Gridelli, Giovanni Palazzolo, Assunta Sgambato, Paolo Maione, Giuseppe Santabarbara
Publikováno v:
Expert Opinion on Drug Safety. 16:471-479
Non-small-cell lung cancer (NSCLC) patients after first-line therapy ultimately suffer progression. At this time, many patients still have a good performance status and can be considered for further active treatment. Two chemotherapeutic agents, doce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b55c12c0ef037d373c467f0f81875a2
https://doi.org/10.1080/14740338.2017.1297795
https://doi.org/10.1080/14740338.2017.1297795
Autor:
Cesare Gridelli, Paolo Maione, Giovanni Palazzolo, Paola Claudia Sacco, Giuseppe Santabarbara, Francesca Casaluce, Antonio Rossi, Assunta Sgambato
Publikováno v:
Expert Opinion on Pharmacotherapy. 18:151-163
Most patients with non-small cell lung (NSCLC), including squamous cell carcinoma, adenocarcinoma and large cell carcinoma, have advanced disease at diagnosis and systemic therapy is the standard-of-care. About 20% of Caucasian patients are affected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14077b0b8e675471ce91400f4286e933
https://doi.org/10.1080/14656566.2017.1280460
https://doi.org/10.1080/14656566.2017.1280460
The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer
Autor:
Assunta Sgambato, Giuseppe Santabarbara, Francesca Casaluce, Cesare Gridelli, Paola Claudia Sacco, Paolo Maione, Antonio Rossi
Publikováno v:
Current Medicinal Chemistry. 24:3-13
Angiogenesis is one of the most important phenomena sustaining tumor development and metastatization, including for non small cell lung cancer (NSCLC). A dominant role in angiogenesis is played by the vascular endothelial growth factor (VEGF) and its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b629e0771a4319c6e247a7cf927f0b26
https://doi.org/10.2174/0929867324666161118125103
https://doi.org/10.2174/0929867324666161118125103
Autor:
Cesare Gridelli, Fortunato Ciardiello, Paola Claudia Sacco, Paolo Maione, Giovanni Palazzolo, Antonio Rossi, Assunta Sgambato, Francesca Casaluce
Publikováno v:
Current Clinical Pharmacology. 11:77-87
Non-small cell lung cancers (NSCLCs) harboring anaplastic lymphoma kinase (ALK) rearrangement are generally responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). Crizotinib is the first-in-class TKI approved as front-line or salvage the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ef1361e81a2f1c73e8e4dd96371fcc5
https://doi.org/10.2174/1574884711666160502124134
https://doi.org/10.2174/1574884711666160502124134
Autor:
Paola Claudia Sacco, Giovanni De Chiara, Cesare Gridelli, Assunta Sgambato, Giuseppe Santabarbara, Tania Losanno, Francesca Casaluce, Emanuela Rossi
Publikováno v:
Expert Review of Clinical Pharmacology. 9:419-428
The advent of immunotherapy has recently expanded the therapeutic options in advanced non-small cell lung cancer (NSCLC). In these patients, the recent efficacy demonstration of antibodies against immune checkpoints: the anti-programmed death-1 (PD-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93607428ef152cca0b33cfedd351314e
https://doi.org/10.1586/17512433.2016.1133289
https://doi.org/10.1586/17512433.2016.1133289